Page 56 - Predicting survival in patients with spinal bone metastasesL
P. 56

                                CHAPTER IV
 Figure 1. Patient flow diagram.
Table 1 summarizes the characteristics of the 1043 patients studied, of whom 542 (52%) were male and 501 (48%) were female. The mean age at start of treatment was 64.8 years (SD ± 12.5 years). At presentation, the majority of patients had no (n=518; 50%) or only minor (n=403; 39%) neurological complaints.
Median follow-up was 6.6 years. The overall median survival was 4.8 months (95%CI 4.3-5.4). In total 984 patients (94%) died during follow-up with a median survival of 4.3 months (95%CI 3.8-4.9). Two-hundred-and-forty-three (23%) patients died within six weeks after starting treatment, whereas 179 (17%) patients survived for more than two years.
54






























































































   54   55   56   57   58